Gilead closes deal to acquire Pharmasset
Gilead Sciences Inc. has completed its acquisition of Pharmasset Inc., a clinical-stage pharmaceutical firm. Gilead said late Tuesday that its subsidiary, Royal Merger Sub II Inc., has finalized the transaction to buy Pharmasset for $137 per share in cash, or about $11.2 billion.